 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...188189190191192193194195196197198...203204» |
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: LOTOS: Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=5500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=2085, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jan 26, 2016
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Sep 2016
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis (clinicaltrials.gov) - Jan 26, 2016
P3, N=93, Enrolling by invitation, Sponsor: AbbVie
Trial primary completion date: Mar 2016 --> Sep 2016 Trial primary completion date: Oct 2020 --> Jul 2020
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Jan 26, 2016
P2, N=220, Recruiting, Sponsor: AbbVie
Trial primary completion date: Oct 2020 --> Jul 2020 Initiation date: Apr 2015 --> Jan 2015
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial withdrawal, Trial primary completion date: TAM-RT: A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers (clinicaltrials.gov) - Jan 26, 2016
P1, N=0, Withdrawn, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Initiation date: Apr 2015 --> Jan 2015 N=27 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> Dec 2015
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: ROCKIES: Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (clinicaltrials.gov) - Jan 25, 2016
P4, N=90, Completed, Sponsor: Amgen
N=27 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> Dec 2015 Active, not recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Jan 22, 2016
P3, N=200, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Oct 2015
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=670, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Feb 2016 --> Oct 2015 Trial primary completion date: May 2018 --> May 2020
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Complete-PS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=660, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: May 2018 --> May 2020 Trial primary completion date: Jun 2017 --> Oct 2018
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Complete-AS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=1120, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2017 --> Oct 2018 Trial primary completion date: Jun 2018 --> Jul 2022
- Trial completion, Enrollment change, Trial primary completion date: ULSPABIT: Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=50, Completed, Sponsor: Diakonhjemmet Hospital
Trial primary completion date: Jun 2018 --> Jul 2022 Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Nov 2016 --> Jan 2016
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study (clinicaltrials.gov) - Jan 20, 2016
P4, N=30, Active, not recruiting, Sponsor: Chung Shan Medical University
Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Nov 2016 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2015
- | Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: ADJUVITE: Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jan 18, 2016
P2/3, N=34, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2015 Trial primary completion date: Nov 2015 --> Nov 2014
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jan 17, 2016
P3, N=833, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2015 --> Nov 2014 Trial primary completion date: Oct 2015 --> Apr 2016
- |||| etrolizumab (RG7413) / Roche
Trial primary completion date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jan 17, 2016
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Mar 2018 --> Nov 2018
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jan 15, 2016
P3, N=400, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Mar 2018 --> Nov 2018 Completed --> Active, not recruiting
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Trial primary completion date, FDG PET: TARGET: Treatments Against RA and Effect on FDG-PET/CT (clinicaltrials.gov) - Jan 15, 2016
P4, N=200, Not yet recruiting, Sponsor: Brigham and Women's Hospital
Completed --> Active, not recruiting Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2019
- |||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Jan 15, 2016
P4, N=90, Recruiting, Sponsor: University of Pittsburgh
Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jan 6, 2016
P3, N=424, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| etrolizumab (RG7413) / Roche
Trial initiation date: HIBISCUS II: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jan 4, 2016
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Initiation date: Nov 2014 --> Jul 2001
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PYRAMID: A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD) (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=5067, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Nov 2014 --> Jul 2001 Active, not recruiting --> Completed
- Humira (adalimumab) / AbbVie
Enrollment change, Trial termination, Trial primary completion date, HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Dec 22, 2015
P=N/A, N=12, Terminated, Sponsor: AbbVie
Active, not recruiting --> Completed N=70 --> 12 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Oct 2015; Recruitment below expectation
- ||| Trial completion, Enrollment change, Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=126, Completed, Sponsor: University of Aarhus
N=70 --> 12 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Oct 2015; Recruitment below expectation Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: PETSPA: Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis (clinicaltrials.gov) - Dec 18, 2015
P4, N=60, Not yet recruiting, Sponsor: Helsinki University
- Humira (adalimumab) / AbbVie
New trial: HELP-AID: Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=140, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis (clinicaltrials.gov) - Dec 16, 2015
P3, N=93, Enrolling by invitation, Sponsor: AbbVie
- |||||||||| Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
New P3 trial: SELECT-COMPARE: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Dec 14, 2015
P3, N=1500, Recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, Real-world evidence, Real-world: ROCKA: Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie
- Trial primary completion date: ABI-RA: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=700, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015 Trial primary completion date: Oct 2015 --> Apr 2016
- |||| remtolumab (ABT-122) / AbbVie
Trial completion, P2 data: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Dec 4, 2015
P2, N=222, Completed, Sponsor: AbbVie
Trial primary completion date: Oct 2015 --> Apr 2016 Active, not recruiting --> Completed
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment closed, Enrollment change, HEOR: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=26, Active, not recruiting, Sponsor: University Hospital Case Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 26
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Trial completion, Trial initiation date: SUSI-CS: Stavanger IBD Study - Cross Sectional (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=210, Completed, Sponsor: Helse Stavanger HF
Recruiting --> Active, not recruiting | N=40 --> 26 Recruiting --> Completed | Initiation date: Dec 2014 --> Apr 2014
- Humira (adalimumab) / Eisai, AbbVie
PK/PD data, Trial primary completion date: Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=30, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Completed | Initiation date: Dec 2014 --> Apr 2014 Trial primary completion date: Jun 2015 --> Dec 2015
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - Dec 4, 2015
P4, N=200, Recruiting, Sponsor: University of Illinois at Chicago
Trial primary completion date: Jun 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
New trial: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Dec 3, 2015
P=N/A, N=90, Recruiting, Sponsor: University of Maryland
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
New trial: THERAPIST: Th17 Responses Evaluated in RA Patients on Inhibitors of TNF? (clinicaltrials.gov) - Dec 2, 2015
P=N/A, N=50, Recruiting, Sponsor: Queen Mary University of London
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, Real-world evidence, Real-world: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan (clinicaltrials.gov) - Nov 27, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Nov 26, 2015
P4, N=64, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Nov 25, 2015
P=N/A, N=445, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=1000 --> 445
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (clinicaltrials.gov) - Nov 25, 2015
P=N/A, N=421, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=1000 --> 445 Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: OPERA: Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 25, 2015
P3, N=180, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - Nov 17, 2015
P4, N=120, Completed, Sponsor: Spanish Clinical Pharmacology Society
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=190 --> 120
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis (clinicaltrials.gov) - Nov 16, 2015
P3, N=46, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=190 --> 120 Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Nov 16, 2015
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Aug 2018 --> Nov 2019
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity (clinicaltrials.gov) - Nov 14, 2015
P4, N=120, Not yet recruiting, Sponsor: Radboud University
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Nov 9, 2015
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Trial primary completion date: Aug 2018 --> Nov 2019 Trial primary completion date: Jul 2016 --> Mar 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: ABILITY-3: Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Nov 9, 2015
P4, N=740, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Jul 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI]) (clinicaltrials.gov) - Nov 6, 2015
P=N/A, N=130, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2016 --> Aug 2018